학술논문

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2021, 39 15, 3p. Supplement: S
Subject
Language
English
ISSN
15277755